105 related articles for article (PubMed ID: 38873259)
1. Blockade of tumor cell-intrinsic PD-L1 signaling enhances AURKA-targeted therapy in triple negative breast cancer.
Takchi A; Zhang M; Jalalirad M; Ferre RL; Shrestha R; Haddad T; Sarkaria J; Tuma A; Carter J; David H; Giridhar K; Wang L; Lange C; Lendahl U; Ingle J; Goetz M; D'Assoro AB
Front Oncol; 2024; 14():1384277. PubMed ID: 38873259
[TBL] [Abstract][Full Text] [Related]
2. Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance.
Jalalirad M; Haddad TC; Salisbury JL; Radisky D; Zhang M; Schroeder M; Tuma A; Leof E; Carter JM; Degnim AC; Boughey JC; Sarkaria J; Yu J; Wang L; Liu MC; Zammataro L; Malatino L; Galanis E; Ingle JN; Goetz MP; D'Assoro AB
Oncogene; 2021 Apr; 40(14):2509-2523. PubMed ID: 33674749
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
4. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
5. NOTCH3 expression is linked to breast cancer seeding and distant metastasis.
Leontovich AA; Jalalirad M; Salisbury JL; Mills L; Haddox C; Schroeder M; Tuma A; Guicciardi ME; Zammataro L; Gambino MW; Amato A; Di Leonardo A; McCubrey J; Lange CA; Liu M; Haddad T; Goetz M; Boughey J; Sarkaria J; Wang L; Ingle JN; Galanis E; D'Assoro AB
Breast Cancer Res; 2018 Sep; 20(1):105. PubMed ID: 30180881
[TBL] [Abstract][Full Text] [Related]
6. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.
Sulaiman A; McGarry S; Li L; Jia D; Ooi S; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Gadde S; Li X; Wang L
Mol Oncol; 2018 Apr; 12(4):423-440. PubMed ID: 29316250
[TBL] [Abstract][Full Text] [Related]
8. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
9. Nuclear Aurora kinase A triggers programmed death-ligand 1-mediated immune suppression by activating MYC transcription in triple-negative breast cancer.
Sun S; Zhou W; Li X; Peng F; Yan M; Zhan Y; An F; Li X; Liu Y; Liu Q; Piao H
Cancer Commun (Lond); 2021 Sep; 41(9):851-866. PubMed ID: 34251762
[TBL] [Abstract][Full Text] [Related]
10. WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.
Castagnoli L; Cancila V; Cordoba-Romero SL; Faraci S; Talarico G; Belmonte B; Iorio MV; Milani M; Volpari T; Chiodoni C; Hidalgo-Miranda A; Tagliabue E; Tripodo C; Sangaletti S; Di Nicola M; Pupa SM
Oncogene; 2019 May; 38(21):4047-4060. PubMed ID: 30705400
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapeutic IL-6R and targeting the MCT-1/IL-6/CXCL7/PD-L1 circuit prevent relapse and metastasis of triple-negative breast cancer.
Haq ATA; Yang PP; Jin C; Shih JH; Chen LM; Tseng HY; Chen YA; Weng YS; Wang LH; Snyder MP; Hsu HL
Theranostics; 2024; 14(5):2167-2189. PubMed ID: 38505617
[No Abstract] [Full Text] [Related]
12. PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer.
Chen C; Li S; Xue J; Qi M; Liu X; Huang Y; Hu J; Dong H; Ling K
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33884962
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer.
Poddar A; Rao SR; Prithviraj P; Kannourakis G; Jayachandran A
Curr Oncol; 2022 Sep; 29(10):6847-6863. PubMed ID: 36290817
[TBL] [Abstract][Full Text] [Related]
14. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
[TBL] [Abstract][Full Text] [Related]
15. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
Front Oncol; 2022; 12():919072. PubMed ID: 35795050
[TBL] [Abstract][Full Text] [Related]
16. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
Sinha A; Paul BT; Sullivan LM; Sims H; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
Oncotarget; 2017 Feb; 8(6):10114-10135. PubMed ID: 28052035
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer.
Saleh R; Taha RZ; Sasidharan Nair V; Alajez NM; Elkord E
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31349612
[TBL] [Abstract][Full Text] [Related]
18. Triple-negative breast cancer cells rely on kinase-independent functions of CDK8 to evade NK-cell-mediated tumor surveillance.
Knab VM; Gotthardt D; Klein K; Grausenburger R; Heller G; Menzl I; Prinz D; Trifinopoulos J; List J; Fux D; Witalisz-Siepracka A; Sexl V
Cell Death Dis; 2021 Oct; 12(11):991. PubMed ID: 34689158
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
20. PD-1/PD-L1 blockade inhibits epithelial-mesenchymal transition and improves chemotherapeutic response in breast cancer.
Antony GR; Littleflower AB; Parambil ST; Subhadradevi L
Med Oncol; 2023 Feb; 40(4):108. PubMed ID: 36842157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
